ABBV
AbbVie Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$294.72
+1.35%Price chart
Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30
Key dataOct 30, 2026
Open$288.86
From 52W high+0.00%
Volume6.88M
Market cap$520.80B
P/E (TTM)83.0x
P/S (TTM)8.1x
Div yield2.35%
Key dataOct 30, 2026
Open
$288.86
From 52W high
+0.00%
Volume
6.88M
Market cap
$520.80B
ValuationView details →
P/E (Fwd)
18.8x
EV/EBITDA
27.6x
P/E (TTM)
83.0x
RSI (14)
74.2
MomentumView details →
1D Return
+1.35%
YTD Return
+29.72%
SummaryUpdated Sep 1, 2026
AbbVie Inc. (NYSE:ABBV) is a pharmaceutical company that was spun off from Abbott Laboratories in 2013. The company emerged as an independent entity to focus exclusively on research-based pharmaceuticals, inheriting Abbott's established drug portfolio including the blockbuster immunology drug Humira. Since its inception, AbbVie has evolved from a company heavily dependent on a single product to a diversified pharmaceutical enterprise with a robust pipeline across multiple therapeutic areas. Today, AbbVie operates as one of the world's largest biopharmaceutical companies, with operations spanning immunology, oncology, neuroscience, and aesthetics.
Similar companies
Latest newsMore news →
AbbVie Inc. shares rose after the company raised its 2026 earnings-per-share outlook.2d agoAbbVie Inc. announced a 5.2% increase in its dividend, effective with dividends paid from February 2027.2d agoAbbVie Inc. reported third-quarter 2026 net revenues of $17.404 billion, up 10.3% year over year, and diluted EPS of $2.37 on a GAAP basis and $3.82 on an adjusted basis.2d ago